Design of potent inhibitors of human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a chimera peptide. by Nomme, J. et al.
pubs.acs.org/jmc Published on Web 07/12/2010 r 2010 American Chemical Society
5782 J. Med. Chem. 2010, 53, 5782–5791
DOI: 10.1021/jm1002974
Design of Potent Inhibitors of Human RAD51 Recombinase Based on BRC Motifs
of BRCA2 Protein: Modeling and Experimental Validation of a Chimera Peptide
Julian Nomme,† Axelle Renodon-Corniere,† Yuya Asanomi,‡ Kazuyasu Sakaguchi,‡ Alicja Z. Stasiak,§ Andrzej Stasiak,*,§
Bengt Norden, ) Vinh Tran,† and Masayuki Takahashi*,†
†UMR 6204 U-3B, Centre National de la Recherche Scientifique & Universite de Nantes, F-44322 Nantes cedex 3, France, ‡Department of
Chemistry, Faculty of Science, Hokkaido University, 060-0810 Sapporo, Japan, §Centre Integratif de Genomique, Faculte de Biologie et de
Medecine, Universite de Lausanne, CH-1015 Lausanne-Dorigny, Switzerland, and )Department of Chemistry and Bioscience, Chalmers
University of Technology, SE-412 96 Gothenburg, Sweden
Received March 6, 2010
Wehave previously shown that a 28-amino acid peptide derived from the BRC4motif of BRCA2 tumor
suppressor inhibits selectively humanRAD51 recombinase (HsRad51).With the aimof designing better
inhibitors for cancer treatment, we combined an in silico docking approach with in vitro biochemical
testing to construct a highly efficient chimera peptide from eight existing human BRCmotifs.We built a
molecularmodel of all BRCmotifs complexedwithHsRad51 based on the crystal structure of the BRC4
motif-HsRad51 complex, computed the interaction energy of each residue in each BRC motif, and
selected the best amino acid residue at each binding position. This analysis enabled us to propose four
amino acid substitutions in the BRC4 motif. Three of these increased the inhibitory effect in vitro, and
this effect was found to be additive. We thus obtained a peptide that is about 10 times more efficient in
inhibiting HsRad51-ssDNA complex formation than the original peptide.
Introduction
ThehumanRAD51protein (HsRad51a) is crucial forDNA
repair processes that are basedonhomologous recombination
between damaged loci and their undamaged copies in sister
chromatids. The protein is thus involved in the repair of a
double-stranded break, the most severe DNA damage.1-4
Efficient DNA repair is usually beneficial for living organ-
isms. However, in the case of cancer cells, their efficient DNA
repair opposes the action of radio- and chemotherapies based
on DNA damaging agents.5-7 Rad51 is often overexpressed
in cancer cells,6-8 and its cellular amount is correlated in some
way to resistance to anticancer treatment and to the degree of
cancer advancement. Rad51 is thus a potential target for
cancer treatment.
In fact, inhibiting the cellular expression of Rad51 directly
by antisense or siRNAor indirectly by affecting the regulatory
protein is found to slowdowntumordevelopment and increase
survival time in mice besides increasing the efficiency of radio-
and chemotherapies.9-13 BRC motifs of human BRCA2
tumor suppressor,which are repeated eight times in theprotein
and are involved in the interaction with HsRad51,14-16 are
reported to inhibit the filament formation of HsRad51, the
first step of the strand exchange reaction, in the cells and
in vitro.17-19 We have previously shown that even a small
peptide of 28 amino acids derived from one of the BRCmotifs
(BRC4-28 peptide) can efficiently and selectively interact with
HsRad51 and dissociate the HsRad51/single-stranded DNA
(ssDNA) complex filament in vitro.20 The peptide is thus a
potential inhibitor of HsRad51 but unfortunately not efficient
enough for medical use.
In this work, we have searched for an optimal amino acid
sequence of the BRCpeptide for the inhibition ofRad51 based
on the existing eight BRC motifs of human BRCA2 protein.
Various BRC motifs of different lengths (from 25 to 69
amino acids) have already been tested for their ability to bind
to HsRad51.16-19 All eight motifs were reported to bind to
HsRad51.16 However, only the structure of the HsRad51-
BRC4motif complex has been elucidated.21We therefore built
molecularmodels of otherBRCmotifs by ahomology strategy
based on the crystal structure of the HsRad51-BRC4 motif
complex. We then computed the interaction energy to
HsRad51 of each residue in the different BRC motifs to find
outwhich amino acid residue boundbest at eachof the binding
positions of the peptide. The sequence thus proposed was then
tested in vitro for its capacity to dissociate the HsRad51-DNA
complex and inhibit the DNA strand exchange activity. The
dissociation of the complex was monitored by measuring the
fluorescencechangeof thepoly(dA) analogue,poly(deoxy-1,N6-
ethenoadenylic acid) (poly(dεA)) or the fluorescence anisotropy
of fluorescein-labeled oligonucleotides, and by electron micro-
scopy observation. The validity of the complex model was also
tested by calorimetric analysis of HsRad51/peptide interactions.
Results
Search for the Minimum Size of an Active BRC4 Peptide.
To design an optimal BRC peptide for the inhibition of
HsRad51 recombinase, we searched for the best-binding
amino acid sequence starting from that of the BRC4 peptide,
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which we had previously studied with respect to its
HsRad51-inhibition effect.20 To alleviate the molecular
modeling and biochemical analysis, we first searched for
the minimum size of BRC4 peptide required for the inhibi-
tory effect. Our previous study showed that separating the
peptide into two parts, i.e., the β-hairpinN-terminal half and
the R-helix C-terminal half, abolishes its ability to bind to
HsRad51 and dissociate the HsRad51-DNA complex
filament,20 indicating that both parts are important for
binding to HsRad51. However, we could not completely
exclude the possibility that the central part of the peptide is
also important for binding as its destruction by fragmenta-
tion abolishes the peptide activity.
The free energy of binding of the BRC4motif to HsRad51
was therefore estimated by a further computational analysis.
We computed the interaction energy (van der Waals short
distance effect terms corrected by long distance Coulombic
interactions) of each overlapping segment of eight amino
acids of peptide instead of that of each amino acid residue to
find out the zone(s) of peptide important for the binding to
HsRad51. This computation was done on the crystal struc-
ture of the HsRad51-BRC4 motif complex. The analysis
revealed two important zones: 1524-FHTASGK-1530 (zone I)
at the N-terminal part and 1541-KVKNLFDE-1548 (zone II)
at the C-terminal part (Figure 1). The results are compatible
with a recent publication by Rajendra and Venkitaraman.22
This indicates that the elimination of only a few amino acids
from the C- or N-terminal part can destroy one of the contact
zones and abolish the inhibitory effect of the peptide.
We tested the effect of deletions on the ability of peptides to
dissociate the HsRad51-DNA complex by monitoring the
fluorescence change of poly(dεA) as previously described20
(Figure 2). The elimination of two amino acid residues from
the N-terminal part (peptide BRC4-26), which conserves the
binding zones, modified only slightly the dissociation capacity
of the peptide. The concentration of this peptide required for
the half-dissociation of theHsRad51-poly(dεA) complexwas
3.5 μMcompared to 2.2 μMfor the original BRC4-28 peptide.
In contrast, thedeletionof twomore residues (peptideBRC4-24c),
which eliminates Phe1524 from binding zone I, strongly dec-
reased the inhibitory capacity (Figure 2A, Table 1), underlining
Figure 1. Interaction interface between the BRC4 peptide and
HsRad51 protein. The BRC4 peptide (ribbon)/HsRad51 (mesh)
interface is visualized from their complex structure.21 The strong
contact zones are noted in the 3-D structure and on the 28-amino
acid sequence. The secondary structure of the peptide is indicated
beside the sequence.
Figure 2. Effect of deletions in the N- and C-terminal parts of the
BRC4 peptide on its capacity to dissociate the HsRad51-DNA
complex. The dissociation of the HsRad51-ssDNA complex by
N-terminal (A) and C-terminal deleted (B) BRC4-motif peptides
was monitored by the decrease in fluorescence intensity of poly-
(dεA) upon stepwise addition of the peptides: BRC4-28 (closed
diamonds), BRC4-26 (closed circles), BRC4-24c (closed squares),
BRC4-24 (stars), and BRC4-24n (open squares). The amino acid
sequence of peptides is noted under the figure to facilitate the
visualization of the deleted parts. The experiments were performed
using 1.5 μM HsRad51 and 3 μM (in bases) poly(dεA) in the
presence of 1 mM ATP.
Table 1. Effect of Deletions of the BRC4 Peptide on Its Capacity to
Dissociate the HsRad51-DNA Complexa
peptide sequence IC50 (μM)
BRC4-28 LLGFHTASGKKVKIAKESLDKVKNLFDE 2.1 ( 0.1
BRC4-26 GFHTASGKKVKIAKESLDKVKNLFDE 3.5 ( 0.2
BRC4-24c HTASGKKVKIAKESLDKVKNLFDE >100.0
BRC4-24 GFHTASGKKVKIAKESLDKVKNLF 11.0 ( 0.3
BRC4-24n FHTASGKKVKIAKESLDKVKNL >40.0
a IC50 was determined as the peptide concentration required for the
half-dissociation of the HsRad51-poly(dεA) complex (1.5 μMHsRad51,
3 μM poly(dεA)) from Figure 2.
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the importance of zone I for the binding toHsRad51. This effect
could be due either to the simple loss of interaction energy of
Phe1524 or to the destabilization of the β-hairpin structure of
zone I caused by the elimination of four amino acids. The first
explanation seems more probable, although we could not com-
pletely exclude the second one because the substitution of
Phe1524byalaninewithoutdeletionofaminoacidsalsoabolishes
the inhibitory effect (data not shown).
The elimination of two amino acid residues from the
C-terminal of BRC4-26 (BRC4-24), which are in binding
zone II, did not abolish the inhibitory effect but decreased it
(Figure 2B). The half-dissociation of the complex was
achieved with 11 μM peptide compared to 3.5 μM for the
peptide that conserves this part (BRC4-26). The deletion of
one more residue (BRC4-24n) completely abolished the
inhibitory capacity (Figure 2B and Table 1), confirming
the importance of zone II for the interaction with HsRad51.
These deletions may not abolish the capacity of the peptide
to form the R-helical structure because the peptide exhibited
a CD signal corresponding to an R-helical structure in the
hydrophobic environment (1 mM SDS) (Figure 3A) just like
the original BRC4-28 peptide.20 The effect of deletions is
certainly a simple loss of contact with HsRad51 by the
elimination of residues without a change in the binding
conformation of the peptide. Supporting this idea, we ob-
served that the substitution of Phe1546 by alanine also
abolishes the inhibitory effect (data not shown).
Search for an Optimal BRC Sequence for HsRad51 Inhibi-
tion.We therefore decided to perform a sequence optimiza-
tion on the 24-amino acid peptide (BRC4-24). To test
systematically the effect of all possible substitutions (19
substitutions) of each residue on 24 positions is too time-
consuming and unfeasible. We used an alternative strategy
based on existing BRC-motif sequences: modeling all the
BRCmotifs based on the known BRC4 structure, taking the
best residue (or segment) at different positions of the peptide
and creating a chimera peptide by fusing them. All eight
BRCmotifs were reported to bind to HsRad51.16 Therefore,
all these motifs would be folded in a similar structure and
interact with HsRad51 in the same way. This would permit
us to use rather simple modeling approach to compute the
interaction energy (see Discussion).
We first searched in the data bank using the BLAST
program for protein segments that are similar in sequence
to the BRC4 motif. All sequences found were consistently
related to the BRC motifs of mammalian BRCA2 proteins.
We therefore tested only the BRC motifs of human BRCA2
protein (Figure 4A). Because the structure of only the BRC4
motif is known, we built a 3-D model of seven other BRC
motifs by a homology approach based on the structure of the
BRC4 motif in the complex with HsRad51 after sequence
alignment (Figure 4A). We then positioned these folded
peptides in the place of the BRC4 motif to build a model of
other BRCmotif-HsRad51 complexes. BRC4 appears to be
a good template in that we did not find any major steric
clashes between any peptide andHsRad51.All constructions
were further refined by energyminimization, first optimizing
the side chain orientation of the peptide and HsRad51, then
the side chain and backbone of the peptide, and finally both
the backbone structure of HsRad51 and that of the side
chains, as described in the Experimental Section.
On the basis of the complex models thus built, we com-
puted the intermolecular interaction energy of each residue
of each BRCmotif forHsRad51 binding.We then compared
the interaction energies of various peptides at a given binding
position (Figure 4B). At almost all the positions, the residues
of the BRC4motif exhibited the best interaction energy (data
not shown), in accord with the observation that BRC4 has
the best affinity for HsRad51 among the BRC motifs.18
However, at four positions, other residues exhibited a better
interaction energy than those of the BRC4 motif: Tyr in the
place of His at 1525, Ser in the place of Ala at 1527 and 1535,
Phe and Trp in the place of Leu at 1545 (Figure 4B).We then
examined the effect of these substitutions in the BRC4motif,
one by one, on the HsRad51 binding by rebuilding the
complex model and recalculating the interaction energy. As
expected from our assumption of an independent energy
contribution of each residue, in all cases except one, our
Figure 3. R-Helical folding potential of BRC peptides: CD analysis. CD spectra of 40 μMBRCpeptides were measured in the presence (lower
parts) and absence (upper parts) of 1 mM SDS. (A) CD of deleted peptides (BRC4-24, black; BRC4-24n, orange; BRC4-24c, cyan). (B)
Substituted peptides (H/Y, magenta; A/S1, olive; A/S2, purple; L/F, navy).
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calculations revealed a significant increase in interaction
energy related to a better affinity of the BRC motif toward
HsRad51 (Figure 4C).
The only exception (Leu1545Trp) was analyzed by com-
paring the source and target contexts (BRC5 and BRC4,
respectively). Graphical display showed that the tryptophan
residue substituting Leu1545 could not penetrate into a
cavity of HsRad51 mainly because of the neighboring bulky
Phe1546 residue. In contrast, in BRC5, the sequence corre-
sponding to Leu(1545)-Phe(1546) of BRC4 is Trp-Leu.
Therefore, in this local but essential restricted zone of
BRC/HsRad51, each initial sequence (Trp-Leu for BRC5
and Leu-Phe BRC4) is sterically acceptable but not the
combination Trp-Phe derived fromour protocol. The cavity,
however, can accommodate two phenylalanine residues
(Figure 5B), and thus the substitution of Leu1545 by Phe
can increase the interaction energy. Graphical display also
showed that the substitution of Ala at 1535 by Ser creates a
hydrogen bonding (Figure 5A) and may thus enhance the
binding. Concerning the substitutions of His at 1525 by Tyr
and Ala at 1527 by Ser, we could not visualize the reason for
the binding enhancement.
Validation of Peptide Modeling: Effect of Sequence Mod-
ifications on the Inhibition of HsRad51-DNA Complex For-
mation and the Strand Exchange Reaction.We first tested the
validity of our modeling by calorimetric analysis of
HsRad51/peptide interactions, then by measuring the BRC
peptide-promoted dissociation of the HsRad51-DNA com-
plex, and finally by evaluating the inhibition of the strand
exchange reaction. We also verified our assumption, using
Figure 4. Proposition of amino acid substitutions of the BRC4 peptide to gain in interaction energy by comparison with the interaction of
other BRC motifs with HsRad51. In (A), the amino acid sequences of the eight human BRC motifs are aligned and the best residues in
interaction energy to HsRad51 at the given position are colored. In (B), the interaction energy of residues of different BRC motifs at given
positions is shown. In (C), relative local energetic gain (ΔEi) is calculated for each substitution. The secondary structure of the BRC4 motif is
presented at the left side to facilitate the identification of substitution positions.
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CD measurements, that the sequence modifications did not
affect the potential folding pattern of the peptides. All the
peptides exhibited a CD spectrum corresponding to a non-
structured state in aqueous solution (Figure 3B). However,
the spectrum was modified upon addition of 1 mM SDS,
which mimics a hydrophobic environment, thus indicating
the formation of anR-helical structure just as for the original
BRC4 peptide. These peptides can be partially folded in an
R-helical structure for interaction withHsRad51 as observed
for the BRC4 motif.21
The isothermal titration calorimeter (ITC) directly mea-
sures the enthalpy of interaction and also enables the deter-
mination of the binding constant and entropy.23,24 This
measurement is thus a useful tool to verify the binding
model. We performed the ITC measurements of the binding
of these peptides to HsRad51 and compared them with the
result for the original peptide of the same size (BRC4-24)
(Typical titration is shown in Supporting Information
Figure S1). The measurements were made using mutated
monomericHsRad51 (HsRad51-F86E) instead of wild type
HsRad51 because the binding of BRC peptides dissociates
HsRad51 oligomers and the ITC measurements would pro-
vide the sum of the binding energy of peptide to HsRad51
and the dissociation energy of HsRad51 oligomers. Using
monomeric HsRad51 enables the binding energy of peptides
to HsRad51 to be measured selectively. The absence of
oligomerization of HsRad51-F86E was verified by molec-
ular sieve chromatography of the protein under the ITC
measurement conditions (data not shown). The results of the
ITCmeasurements were analyzed according to a one-binding-
site model and nicely fitted for all the cases with a binding
stoichiometry of about 1 (1.1 ( 0.1 peptide-HsRad51
monomer). The analysis was thus self-consistent. Further-
more, the analysis with a model of two binding sites did not
provide good fitting.
The binding parameters thus obtained support our pre-
diction concerning the substitutions of His1525Tyr (H/Y),
Ala1535Ser (A/S2), and Leu1545Phe (L/F): all these sub-
stitutions increased the binding affinity of peptide to
HsRad51 (Table 2). Furthermore, in the case of Leu1545Phe
substitution, the ITCmeasurements showed enhancement in
the reaction entropy (Δ(ΔS) positive) without significantly
changing ΔH. This is in accord with the modeled complex
(Figure 5B), in which the hydrophobic interaction is en-
hanced and thus the entropy of interaction should be in-
creased.Good accord between the experimental data and the
model was observed also for Ala1535Ser substitution (A/S2
peptide). The visualization of complex shows creation of an
extra hydrogen bond and predicts improvement in enthalpy
of interaction. The ITC measurements shows that the
Ala1535Ser (A/S2) substitution enhanced the enthalpy
(Δ(ΔH) negative) slightly disfavoring the entropy of reaction
(Table 2).
Figure 5. Effect of amino acid substitutions on the contact with
HsRad51. (A) Substitution of Ala1535 by serine creates a new
hydrogen bonding with Glu213 of HsRad51. (B) Substitution of
L1545 by phenylalanine strengthens the interaction with a hydro-
phobic pocket of HsRad51 (gray surface).
Table 2. Calorimetric Analysis of HsRad51/Peptide Interactionsa
peptide
K
(105 M-1)
ΔH
(kcal/mol)
Δ(ΔH)
(kcal/mol)
ΔS
(cal/mol/deg)
Δ(ΔS)
(cal/mol/deg)
BRC4-24 1.4 ( 0.4 -12.3 ( 1.6 -18
H/Y 3.8 ( 2.8 -14.1 ( 2.5 -1.5 -20 -2
A/S1 <0.1 nd nd nd nd
A/S2 5.2 ( 1.5 -14.3 ( 2.6 -2.0 -21 -3
L/F 7.3 ( 4.3 -11.5 ( 2.5 þ0.8 -14 þ4
a nd: not determined.
Figure 6. Effect of amino acid substitutions of the peptide on its
capacity to dissociate the HsRad51-DNA complex. The dissocia-
tion of the HsRad51-ssDNA complex by modified BRC4-motif
peptides was monitored by the decrease in fluorescence intensity of
poly(dεA) upon stepwise addition of the peptides as in Figure 2.
Open diamonds, A/S1 (Ala1535Ser); open circles, H/Y (His1525Tyr);
closed squares, L/F (Leu1545Phe); crosses, A/S2 (Ala1535Ser); open
triangles, Y-S2-F peptide with three amino acid substitutions.
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In contrast to these peptides, we did not observe any
significant heat change upon injection of peptide, in which
Ala at 1527 is substituted by Ser (A/S1 peptide). There may
be no significant interaction, i.e., decrease in the binding
affinity by this substitution. The residue is situated in the
β-turn structure (Figure 4C), and thus the substitution may
decrease the stability of this active conformation and, con-
sequently, the capacity to bind to the HsRad51.
We then tested the capacity of these peptides to cause
dissociation of the HsRad51-ssDNA complex. The dissocia-
tion capacity was first monitored by the decrease in fluore-
scence intensity of poly(dεA), a fluorescent etheno analogue of
poly(dA) (see the Experimental Section). All the substitutions,
except that of Ala at 1527 by Ser (A/S1 peptide), were found to
increase the dissociation capacity of the peptide: lower con-
centrations of peptide were sufficient to cause dissociation of
the HsRad51-poly(dεA) complex (Figure 6). The concentra-
tions of peptide required for half-dissociation decreased from
11 μM (BRC4-24) to 7 μM for His1525Tyr (H/Y peptide), to
2.5 μM for Ala1535Ser (A/S2 peptide) and to 5 μM for
Leu1545Phe (L/F peptide) substitutions (Table 3). The effect
was rather additive: the peptide in which the three residues
were substituted (Y-S2-F peptide) exhibited better efficiency
and the half-dissociation occurred at 1.5 μM. The apparent
Ki was estimated using the formula (Ki = [peptide]total -
[HsRad51]/2), with the assumption that the binding stoichio-
metry of peptide toHsRad51 is 1 permonomer as indicated by
the ITC measurements (see Supporting Information). We
observed that theKi of the peptide with the three substitutions
became less than 1/10 of that of the original peptide (Table 3).
Weobtained similar results using the fluorescein-labeled oligo-
(AGT)12 oligonucleotide (Table 3), showing that the increase
in the dissociation activity is independent of DNA sequence as
expected.
The action of the modified peptide on the preformed
HsRad51-ssDNA complexes was further verified by electron
microscopy observations of complexes formed with ΦX174
ssDNA (Figure 7). In the absence of the peptide, we observed
regularly structured extended HsRad51-ssDNA filaments as
reported earlier for these types of complexes25,26 (Figure 7A).
When 10 μM of Y-S2-F BRC peptide was added to the
preformed HsRad51-ssDNA complexes, the filaments lost
their regularity and revealed the presence of kinks, presumably
corresponding to points where HsRad51 started to depoly-
merise and dissociate from ssDNA (Figure 7B). At a still
higher concentration of Y-S2-F BRC peptide (50 μM), the
preformed HsRad51-ssDNA complexes almost completely
dissociated (Figure 7C). Thus, we have demonstrated by EM
that the peptide can dissociate even large HsRad51-ssDNA
complexes and have confirmed the results of assays based on
fluorescence measurements.
In contrast to these substitutions, the substitution of Ala at
1527bySer (A/S1) decreased the efficiency: thehalf-dissociation
required more than 40 μM peptide (Figure 6, Table 3). The
substituted peptide may not bind efficiently to HsRad51, as
indicated by the ITC measurements (Table 2), and could not
dissociate the Rad51-DNA complex.
Finally, we tested the inhibitory effect of peptides on the
DNA strand exchange activity of HsRad51. The strand
exchange reaction between a short single-stranded oligo-
nucleotide and a double-stranded oligonucleotide of the same
sequence was performed in the presence of various concentra-
tions of peptides. As expected, the strand exchange reaction
wasmore efficiently inhibitedby substitutedpeptides (Figure 8)
corresponding well to the increase in the ability to promote the
dissociation of the HsRad51-DNA complex.
Discussion
On the basis of the relevant starting point for HsRad51
inhibition (crystallographic data of the complex formed with
the BRC4 motif), our goal was to design more efficient
BRC-motif peptides. The prediction of ligand binding affinity
is one of the most challenging applications of computational
Table 3. Effect of Amino Acid Substitutions of the BRC4 Peptide on Its Capacity to Dissociate the HsRad51-DNA Complexa
peptide sequence
poly(dεA)
IC50 (μM)
oligo(AGT)12
IC50 (μM) Ki (μM)
BRC4-24 GFHTASGKKVKIAKESLDKVKNLF 11.0 ( 0.3 6.00( 0.03 10.0
H/Y GFYTASGKKVKIAKESLDKVKNLF 7.0 ( 0.3 2.70( 0.02 6.0
A/S1 GFHTSSGKKVKIAKESLDKVKNLF >40 >40.0
A/S2 GFHTASGKKVKISKESLDKVKNLF 2.5 ( 0.1 2.00( 0.02 1.8
L/F GFHTASGKKVKIAKESLDKVKNFF 5.0 ( 0.2 2.60( 0.02 4.2
Y-S2-F GFYTASGKKVKISKESLDKVKNFF 1.5 ( 0.1 1.05( 0.01 0.75
a IC50 was determined as in Table 1 and apparent Ki as the concentration of free peptide at half-dissociation.
Figure 7. Electron microscopy observation of the effect of Y-S2-F BRC peptide on the HsRad51-ssDNA complexes. HsRad51-ssDNA
filaments formed betweenHsRad51 (5 μM)andΦX174 ssDNA (10 μMinbases) were observed by electronmicroscopy after addition of 10 μM
(B) or 50 μM (C) Y-S2-F BRC peptide or without peptide (A).
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chemistry. Ultimately, ranking compounds according to their
estimated affinities to a given molecule by means of molecular
mechanics scheme is of particular interest for structure-based
drug design. From a theoretical point of view, free energy is the
potent value to estimate binding constants and corresponding
calculationshave hugely progressedbecause of the improvement
of force fields and development of numerical algorithms and
protocols in conjunctionwith considerable progress in computer
power. Assuming that a set of experimental binding data is avai-
lable, reproducing them by computational methods could be
done by numerous protocols mainly depending on the expected
accuracy and theoretical complexity.
To one extremity, the simplest way is to use empirical or
statistical multivariate equations (QSAR). A scoring function
is a simple estimation of relative binding affinities for virtual
screening methods mainly based on shape and chemical
complementarity. At the other extremity, most rigorous
methods toget access to the ligand-receptor binding enthalpy
are quantummechanics (QM) calculation or at least a combi-
nation of quantummechanics andmolecularmechanics (QM/
MM).But so far, these approaches are excessively expensive in
termof engaged computational resources. In addition, solvent
effects are not always well taken into account and, usually, an
appropriate treatment would require implicit solvent models
where water is assimilated to a continuum dielectric medium.
This approximationyielded to solvation free energieswith two
protocols: Poisson-Boltzmann/surface area (MM-PBSA)
and generalized Born/surface area (MM-GBSA). Thus, the
exploration of the conformational space will be achieved by
very long MD simulations to determine equilibrium averages
with methods of free-energy perturbation (FEP) or thermo-
dynamic integration (TI).
With an intermediate accuracy, classical molecular me-
chanics (MM) approaches appear as a good balance between
computer time and energy accuracy for large molecular
systems by taking into account both induced fit of all molec-
ular partners.Thus free energy calculations canbe achievedby
different ways depending on approximations used. Basically,
most force fields employed these two last decades are ex-
pressed as the sum of independent terms of bonded and
nonbonded interactions, whatever the mathematical expres-
sion of each term is. Bonded interactions are based on internal
parameters of molecules covalently described (bonds, angles,
and dihedrals), and obviously these terms do not participate
to the affinity between molecules. Nonbonded interactions
mainly include van der Waals short distance effect terms
(generally expressed by a repulsive-attractive Lennard-Jones
6-12 potential) corrected by long distance Coulombic inter-
actions (between point charges centered on each atom).When
applied to atoms of the same molecule, these two types of
interactions participate to its potential energy. Conversely,
calculated between atoms of two different molecules, the sum
of these nonbonded interactions is defined as interaction
energy by most softwares (Discover, CHARMM, ...).
This term is the energy criterionusedhere. Practically,when
calculations are done for a series of ligands (similar in shape
and chemical properties) interacting with the same target
molecule, these interaction energies could be qualitatively
assimilated to relative binding affinities if each ligand-target
complex minimized is the most probable docking solution.
Furthermore, this simple scheme does not take into account
the role of explicit water molecules capable to significantly
modify the affinity between two molecules measured in
vacuum. For these reasons, we chose a relatively simple
modeling approachbased on interaction energies and checked
how good it is as a predictive tool to in silico reveal potential
oligopeptide leads prior to any biochemical syntheses and
further in vitro activity tests. Finally, we considered that
interaction energy values already successfully used in several
previous papers27-29 were adequate with regards to the model-
ing construction scheme (basically by homology to initial
BRC4-28 peptide, no water molecule taken into account).
For this purpose, we took advantage of all the biological
data available. An initial search for BRC4 sequence similarity
using theBLASTalgorithmyielded exclusivelyBRCmotifs of
mammalian BRCA2 proteins. This strengthens the possible
functional specificity of these motifs, at least for HsRad51
interaction. The 3-D folding of BRC4 observed in the crystal-
lographic complex was used as a pattern to model all other
BRC motifs in complex with HsRad51. Because of the
geometrical features of the pattern, we could assume additiv-
ity of local binding energies. This enabled us to design an
optimal peptide by selecting the best amino acid residue (or
segment) at a given binding position and fusing them as a
chimera peptide. We have thus gained a 10 times more
efficient peptide by combining the eight existing human
BRC motifs. This approach alleviates the model building
compared to the systematic substitution of amino acids in
the peptide. Furthermore, it can potentially replace a segment
of the peptide while the systematic substitution approach
allows only one amino acid residue to be changed at a time.
The approach could also avoid unexpected conformational
change of peptide upon amino acid substitution. The method
Figure 8. Inhibition of the DNA strand exchange reaction by the
modified BRC4 peptides. The HsRad51-promoted (0.5 μM) strand
exchange reaction between single-stranded and double-stranded
oligonucleotides in the presence of indicated concentrations of
BRC4 peptides was analyzed by quantifying the reaction product
(B) after its separation by polyacrylamide gel electrophoresis (A) as
described in the Experimental Section. Stars, BRC4-24; circles, H/Y;
squares, L/F; crosses, A/S2; triangles, Y-S2-F peptides.
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is thus interesting and could be applied to other systems in
which the interacting segment is repeated or a protein family is
involved.
The observation that 3 of our 4 propositions are experi-
mentally confirmed supports our assumption that all BRC
motifs ofBRCA2bind toHsRad51 in the same conformation.
The unexpected effect of the Ala1527Ser substitution, i.e., the
decrease in inhibitory effect, may, in contrast, be due to
destabilization of the β-turn organization at the N-terminal
part, in which Ala1527 is situated. Further analysis is in
progress to examine this explanation bymore vigorousmodel
building including the dynamics and also by NMR measure-
ments. Except for this part, the motifs bind in a rather
extended form and each residue interacts with HsRad51
roughly independently of its neighboring residues. This is
supported by the observation that the increase in efficiency
by substitution is rather additive. Our model building is also
supported by ITC calorimetric measurements: as expected,
Leu1545Phe substitution improves the entropy contribution
and Ala1535Ser substitution enhances the enthalpy.
These observations suggest that stabilization of the active
conformation would further increase the efficiency of the
peptide. The peptide is not structured in free form in solution
according to the CD measurements while it should be orga-
nized in β-turn and R-helix to bind to HsRad51 (Figure 3), as
observed in the crystal structure of the complex.21 Formation
or stabilization of the active form before binding to HsRad51
certainly facilitates the interactionand enhances the inhibitory
effect. In accord with this concept, the ITC calorimetric
analysis showed that the binding of peptide to HsRad51 is
disfavored by entropy (ΔS negative), suggesting that one part
of the binding energy is used for the organization of the
peptide from random coil. The importance of R-helix was
suggested by our recent observation that the some substitu-
tions, which should not affect the interaction with HsRad51
but disfavors R-helix formation, inhibits the in vitro strand
exchange reaction less efficiently.
It has been reported recently that in vitro binding of
HsRad51 to ssDNA was promoted by BRC motifs supplied
either in a form of BrcA2 domain containing the eight BRC
repeats or in a form of 35 amino acid peptide.30,31 The same
authors observed however that formation of HsRad51-
dsDNA complexes was inhibited by the addition of BRC
motifs and that both of the effects resulted in a stimulation of
HsRAD51-mediated strand exchange reaction. We were
especially concerned by the reported stimulation of HsRad51
recombination by the short peptide of 35 amino acids because
this of coursewould compromise our plan touse peptideswith
BRC repeats as inhibitors of HsRad51-mediated DNA repair
by homologous recombination.30 However, the peptides used
by us did not show stabilization of HsRad51-ssDNA com-
plexes even at low peptide concentration. This applied not
only to complexes formed with synthetic oligonucleotides but
also to complexes formedwith longΦX174 ssDNAmolecules
with natural base sequence. We think that the fact that our
peptides were shorter than these used by Carreira et al.30 is
likely the cause of the difference. A very recent work by
Rajendra and Venkitaraman showed the importance of
LFDE sequence at the C-terminal of BRC4motif for binding
to HsRad51 and concluded that this motif stimulates
HsRad51 oligomerization.22 In the case of 35 amino acids
peptide studied byCarreira et al., the LFDEsequencewas still
followed by additional three amino acids, which permitted
this motif to be in its natural environment. Our peptides that
range from24 to28aminoacids have a shorterC-terminal and
either miss the DE residues completely or terminate just after
LFDE motif, which apparently interferes with possible sti-
mulatory action of LFDE sequence on the formation of
HsRad51-ssDNA complexes. According to Rajendra and
Venkitaraman the inhibitory module of each repeat is posi-
tioned close toN-terminal of 35 amino acid BRC repeat. This
module has the sequence FxxA and all our peptides that
showed destabilizing action on HsRad51 complexes con-
tained this entire sequence and was still flanked by at least
one amino acid toward the N-terminal. Therefore, our results
are fully consistent with these byRajendra andVenkitaraman
and show that BRC repeat fragments containing only fully
functional inhibitory modules with the FxxA sequence can be
used for specific inhibitionsofHsRad51-meditedhomologous
recombination. With further improvements, such peptides
may become efficient enough for use at the cellular level and
could become a promising candidate for the design of anti-
cancer drugs.
Conclusions
Taking advantage of the reported crystal structure of BRC
motif-Rad51 complex, we designed more efficient chimera
peptide from the existing eight human BRC motifs with the
help of a rather simple in silico docking approach and verified
its efficiency by in vitro biochemical testing.
Experimental Section
Modeling Methods. The atomic coordinates of the BRC4
peptide-HsRad51 complex were taken from the 3-D structure
determined by X-ray crystallography at 1.7 A˚ resolution21
(Protein Data Bank access no. 1N0W). Amino acid sequences
similar to BRC4 were searched for in the SwissProt data bank.
The sequence alignmentwas carried out using the Blast program
accessible at Po^le Bioinformatique Lyonnais (http://pbil.univ-
lyon1.fr). Visualization of the complex and interaction energy
calculations were performed with the InsightII Accelrys
software32 under the CFF91 force field33,34 and using a steepest
descent algorithm. Intermolecular binding energies between
each amino acid residue of the BRC peptides and HsRad51
were estimated using the DOCKING option, taking into ac-
count the electrostatic and van derWaals nonbounded energies.
Intermolecular binding energies between the segments of 7/8
amino acids of the BRC peptides and HsRad51 were also
computed in the same manner.
Model building of various BRC motifs in complex with
HsRad51was based on the crystal structure of theBRC4peptide-
HsRad51 complex:21 after sequence alignment, each peptide was
folded and positioned to HsRad51 on the basis of the BRC4
peptide backbone. From these initial constructions, only a few
changes in the orientation of the peptide side chains or HsRad51
residues were necessary to avoid local steric conflict. Next, the
complex structures were refined by 20000 cycles of minimization,
keeping their backbone structure as observed in the crystal struc-
ture. A supplemental step of 20000 cycles of minimization without
any constraints on the BRC peptides but keeping the backbone
structure of HsRad51 was performed to monitor the adaptation
and the relaxation of BRC peptides in the HsRad51 complex
context. Finally, 20000 cycles of minimization were performed
without any constraints.
ProteinPreparation.Wild typeHsRad51 andHsRad51-F86E,
which cannot form polymers,21 were prepared as described in
Nomme et al.:20 the N-terminal hexahistidine-tagged HsRad51
were expressed in the JM109(DE3) strain of Escherichia coli that
also carries an expression vector for the minor tRNAs
(Codon(þ)RIL, Novagen), and purified on nickel-nitrilotriacetic
5790 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 15 Nomme et al.
acid (Ni-NTA) agarose (Invitrogen). HsRad51-F86Ewas eluted
with a linear gradient of 10-60 mM imidazole while wild type
HsRad51 was eluted with a gradient of 60-500 mM imidazole.
The hexahistidine tag was then removed from the HsRad51
portion with thrombin (Amersham Biosciences), and the proteins
were further purified by chromatography on a MonoQ column
(HealthcareBiosciences). Protein concentrationswere determined
using the Bio-Rad protein assay kit with bovine serum albumin
(Pierce) as a standard protein.
Peptides.Thepeptides spanning the part of theBRC4motif of
BRCA2 protein were prepared byNeosystem (France): BRC4-28
(1521-1548), BRC4-26 (1523-1548), BRC4-24 (1523-1546),
BRC4-24c (1525-1548), BRC4-24n (1522-1545). The amino
acid composition and purity of the peptides were verified by mass
spectroscopyandHPLCanalysis (Supporting InformationFigure
S2). The purity of all the peptides except BRC4-28 (94%), H/Y
(94%), and Y-S2-F (94%) was more than 95%. All modified
BRC4-24 peptides, in which one or more residues were replaced
with another, were synthesized by the Fmoc solid-phase method
using the ABI433A peptide synthesizer (PE Applied Biosystems,
USA). The peptides were deprotected at the side chains and
liberated from the resin by reaction with Reagent K (9 mL of
trifluoroacetic acid (TFA), 0.5 mL of water, 0.5 mL of phenol,
0.5 mL of thioanisole, and 0.25 mL of ethanedithiol) for 3 h at
room temperature. The crude peptides were purified by reversed-
phase high performance liquid chromatography (RP-HPLC) on a
C8 column (VYDAC, USA) and eluted with a linear gradient of
0.05%TFAand acetonitrile (Supporting Information Figure S3).
Molecular weights were confirmed by MALDI-TOF mass spec-
trometry on Voyager DE-PRO (PerSeptive Biosystems, USA).
The N-terminal of all the peptides was acylated.
Dissociation of HsRad51-DNAComplex Filament.The BRC
peptide-promoted dissociation of the HsRad51-single-stranded
DNA (ssDNA) complex filament wasmonitored by the change in
fluorescence of poly(dεA), the poly(dA) analogue, and the change
in fluorescence anisotropy of fluorescein-labeled oligonucleotide
(oligo(AGT)12) (Genset, France).
35 Poly(dεA) was prepared by
chemical modification of poly(dA) (Pharmacia), as described in
ref 36, and its fluorescence was measured at 410 nm (bandwidth:
5 nm) with excitation at 320 nm (bandwidth: 3 nm) in an FP-6500
spectrofluorimeter (Jasco, Japan). The fluorescence anisotropy
was measured in a J-715 fluorescence polarimeter (Jasco, Japan)
averaging over 20 measurements. Most experiments were per-
formed at 25 C in 20 mM (in phosphate) sodium phosphate
buffer, pH 7.4 containing 50 mMNaCl, 1 mMMgCl2, and 1 mM
ATP. The buffer was filtered on a nitrocellulose filter (pore size:
0.2 μm) (Pall Corporation, USA) and degassed. The concentra-
tion of HsRad51 was 1.5 μM and that of poly(dεA) was 3 μM in
bases for poly(dεA) experiments, and 0.5 μM of HsRad51 and
1 μM in bases of oligo(AGT)12 for the anisotropy experiments.
Electron Microscopy. The BRC peptide-promoted dissocia-
tion of HsRad51-ssDNA complexes was also monitored by
electron microscopy. The HsRad51-ssDNA complex was
formed by incubation of circular ΦX174 ssDNA (10 μM in
bases) withHsRaD51 (5 μM) in a 20mM (in phosphate) sodium
phosphate buffer, pH 7.4 containing 1 mM MgCl2 and 5 mM
ATP for 15 min at 37 C. BRC peptide was then added at the
indicated concentrations. After a further 15 min of incubation,
glutaraldehyde was added to the final concentration of 0.1% to
fix protein-DNAcomplexes. The fixationwas performed for 15
min at 37 C. Samples of the reactions were then diluted 10-fold
in 5mMmagnesium acetate and used for adsorption onto glow-
discharged, carbon-coated electron microscopy grids. After
negative staining in 2% uranyl acetate,37 the images of samples
were recorded at a magnification of 22000 using a Philips CM12
electron microscope.
Strand Exchange Assay. The DNA strand exchange reaction
between 58-mer ssDNAand the IRD-labeled homologous 32-mer
double-stranded DNA was performed as previously described.20
Then0.5μMofHsRad51 in thepresenceof indicated concentrations
of BRC4 peptides was incubated with a 58-mer ssDNA (100 nM
in fragment) in 10 μL of standard reaction buffer containing
20 mM Tris-HCl (pH 8.0), 1 mMATP, 1 mMDTT, 100 μg/mL
BSA, 20 mM MgCl2, 2 mM creatine phosphate, 75 μg/mL
creatine kinase, and 2% glycerol, at 37 C for 20 min. The
reaction was initiated by adding the 32-mer dsDNA (10 nM in
fragment). After 1 h of incubation at 37 C, the reactions were
stopped by the addition of 0.7%SDS and 0.7mg/mL proteinase
K (RocheMolecular Biochemicals). The reactionmixtures were
further incubated for 10 min at 37 C. After addition of loading
dye, the reaction products were subjected to electrophoresis on
15% polyacrylamide gel. The electrophoresis was carried out
with TBE buffer (90 mM Tris, 90 mM boric acid and 2 mM
EDTA) and applying 10 V/cm for 3 h. The products were
visualized by detection of IRD-800.
CDMeasurements.CD signals of peptides weremeasured in a
J-810 CD spectrometer (Jasco, Japan) equipped with a Peltier
effect temperature controller and using a 1 cm  0.2 cm quartz
cell with four windows (Hellema, Germany), allowing measure-
ment with either a 1 or 0.2 cm path length. The CD spectra were
measured from 260 to 190 nm in step mode (bandwidth: 2 nm;
interval: 0.1 nm; response time: 0.125 s; path length: 0.2 cm;
temperature: 20 C) and averaged over two scans to increase the
signal-to-noise ratio. The variation in the CD signal at 220 nm
with rising temperature was measured (bandwidth: 10 nm,
interval: 0.1C; response time: 1 s, path length: 1 cm) by increasing
the temperature from20 to 85 Cat a rate of 1 C/min.All theCD
experiments were performed with 45 μM peptide in 20 mM (in
phosphate) sodium phosphate, pH 6.8.
Isothermal Titration Calorimetry (ITC) Measurements. ITC
measurements for the binding of BRC peptides to monomeric
HsRad51 (HsRad51-F86E) were performed in a Microcal
V200 ITC apparatus (filtering time: 2 s; injection interval: 120
s; syringe rotation: 1000 rpm) at 25 C.The bufferwas 20mM(in
phosphate) sodium phosphate, pH 7.4 with 50mMNaCl, 1mM
MgCl2, and the protein concentration was 5 μM. The analysis
was carried out with a single-binding-site model. The experi-
ments were repeated at least twice.
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